📣 VC round data is live. Check it out!
- Public Comps
- Salus
Salus Valuation Multiples
Discover revenue and EBITDA valuation multiples for Salus and similar public comparables like Cerus, Arjo, Menicon, Paul Hartmann and more.
Salus Overview
About Salus
Salus is a Slovenia-based company engaged in the wholesale and distribution of medical products. It offers medicines, medical devices, medical supplies, dietary supplements, cosmetics to hospitals, pharmacies, and other customers.
Founded
1969
HQ

Employees
413
Website
Sectors
Financials (FY)
EV
$612M
Valuation Multiples
Start free trialSalus Financials
Salus reported last fiscal year revenue of $811M and EBITDA of $35M.
In the same fiscal year, Salus generated $97M in gross profit, $35M in EBITDA, and $19M in net income.
Salus P&L
In the most recent fiscal year, Salus reported revenue of $811M and EBITDA of $35M.
Salus is profitable as of last fiscal year, with gross margin of 12%, EBITDA margin of 4%, and net margin of 2%.
Financial data powered by Morningstar, Inc.
Salus Stock Performance
Salus has current market cap of $598M, and enterprise value of $612M.
Market Cap Evolution
Salus' stock price is $72.76.
Salus share price decreased by 0.4% in the last 30 days, and increased by 104.9% in the last year.
Salus has an EPS (earnings per share) of $2.36.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $612M | $598M | 1.1% | -0.4% | -7.3% | 104.9% | $2.36 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialSalus Valuation Multiples
Salus trades at 0.8x EV/Revenue multiple, and 17.3x EV/EBITDA.
Salus Financial Valuation Multiples
As of May 27, 2026, Salus has market cap of $598M and EV of $612M.
Salus has a P/E ratio of 30.8x.
Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Salus Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.


Salus Margins & Growth Rates
In the most recent fiscal year, Salus reported gross margin of 12%, EBITDA margin of 4%, and net margin of 2%.
Salus Margins
Salus Growth Rates
Data powered by FactSet, Inc. and Morningstar, Inc.
Salus Operational KPIs
Salus' revenue per employee in the last FY averaged $2.0M, while opex per employee averaged $0.2M for the same period.
Data powered by FactSet, Inc. and Morningstar, Inc.
Salus Competitors
Salus competitors include Cerus, Arjo, Menicon, Paul Hartmann, Universal Vision, Prim, Standard Glass Lining, Tristel, Stille and Bastide Le Confort Médical.
Most Salus public comparables operate across Medical Supplies.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| Last FY | LTM | 2027E | Last FY | LTM | 2027E | |
| 2.4x | 2.3x | 58.8x | 41.3x | |||
| 0.6x | 0.6x | 3.7x | 3.7x | |||
| 1.4x | 1.3x | 8.9x | 7.7x | |||
| 0.4x | - | 3.9x | - | |||
| 2.4x | 2.3x | 5.2x | 5.3x | |||
| 0.9x | - | 6.3x | - | |||
| - | - | - | - | |||
| 3.8x | 3.5x | 13.9x | 12.7x | |||
This data is available for Pro users. Sign up to see all Salus competitors and their valuation data. Start Free Trial | ||||||
Salus M&A Activity
Salus has acquired 1 company to date.
Last acquisition by Salus was on August 1st 2025. Salus acquired Farmadent for $9M (EV/Revenue multiple of ).
Latest Acquisitions by Salus
| Description | Farmadent is a Slovenia-headquartered wholesaler distributing medicines, medical devices, and consumer health products to pharmacies across the Balkans. Based in Ljubljana, it supplies antibiotics, analgesics, and diagnostics from Merck and Roche, maintaining a 20,000-square-meter warehouse. Farmadent holds GDP certification and delivers to 2,000 outlets in Slovenia, Croatia, and Serbia. |
| HQ Country | |
| HQ City | Maribor |
| Deal Date | 1 Aug 2025 |
| Valuation | $9M |
| EV/Revenue | |
| EV/EBITDA | |
This data is available for Pro users. Sign up to see all Salus acquisitions and their M&A valuation multiples. Start Free Trial | |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Salus
| When was Salus founded? | Salus was founded in 1969. |
| Where is Salus headquartered? | Salus is headquartered in Slovenia. |
| How many employees does Salus have? | As of today, Salus has over 413 employees. |
| Is Salus publicly listed? | Yes, Salus is a public company listed on Ljubljana Stock Exchange. |
| What is the stock symbol of Salus? | Salus trades under SALR ticker. |
| When did Salus go public? | Salus went public in 1999. |
| Who are competitors of Salus? | Salus main competitors include Cerus, Arjo, Menicon, Paul Hartmann, Universal Vision, Prim, Standard Glass Lining, Tristel, Stille, Bastide Le Confort Médical. |
| What is the current market cap of Salus? | Salus' current market cap is $598M. |
| What is the current revenue of Salus? | Salus' last fiscal year revenue is $811M. |
| What is the current EV/Revenue multiple of Salus? | Current revenue multiple of Salus is 0.8x. |
| Is Salus profitable? | No, Salus is not profitable. |
| How many companies Salus has acquired to date? | As of May 2026, Salus has acquired 1 company. |
| What was the largest acquisition by Salus? | $9M acquisition of Farmadent on 1st August 2025 was the largest M&A Salus has done to date. |
| What companies Salus acquired? | Salus acquired Farmadent. |
| In how many companies Salus has invested to date? | Salus hasn't invested in any companies yet (or none have been disclosed publicly). |
See public comps similar to Salus
Lists including Salus
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.
